May 6, 2026 / New Taipei City

Panlabs Biologics Inc. (hereafter “Panlabs”), a company with over 50 years of expertise in microbial and fermentation technologies, today announced the launch of its second facility in New Taipei Industrial Park. The new site is equipped with fermentation systems of up to 500 L and is positioned as a key platform for process scale-up and industrialization validation, strengthening the transition from laboratory research to real-world applications.

Panlabs provides integrated, one-stop services spanning strain improvement, process development, and scale-up studies. With more than 300 completed domestic and international projects, its technologies have been applied across the pharmaceutical, chemical, biotechnology, and food industries. The new facility bridges a critical gap between early-stage R&D and pilot-scale production, helping clients navigate one of the most challenging phases in biotech development—process scale-up.

Beyond the installation of 500 L fermentation systems, the facility is built around two core capabilities. On the process side, it supports scale-up and pilot validation, including process optimization, scale-up evaluation, and stability assessment, thereby reducing downstream development risks. On the application side, the facility features a dedicated cell laboratory that integrates customized recombinant protein design, expression, and purification, along with cell-based functional assays. This extends Panlabs’ service scope from molecular design to biological activity validation, enhancing both depth and value.

According to Panlabs, the new facility will significantly improve the efficiency of strain development, protein expression, and process optimization. It is expected to shorten development timelines, reduce translational risks, and accelerate the path to commercialization. The site will also support the development and future production planning of Panlabs’ proprietary products, further strengthening its overall competitiveness.

Looking ahead, Panlabs will continue to advance its fermentation and protein expression platforms while expanding global collaborations. Through an integrated service model spanning strain development, process scale-up, and application validation, the company aims to be a key partner in the biotechnology industry, enabling clients to bring high-value applications to market more efficiently.